BioSpace News Archive

Axonics, Inc reported preliminary unaudited revenue for the fiscal year ended December 31, 2022 and issued fiscal year 2023 revenue guidance.

Eargo, Inc. today announced that its Board of Directors has approved a 1-for-20 reverse stock split of the Company’s common stock.

G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that on January 19th, 2023, at 11:30 AM EST, G1’s Chief Executive Officer Jack Bailey will provide a corporate presentation during the virtual 2023 B. Riley Securities 3rd Annual Oncology Conference.

Bicycle Therapeutics plc today announced that monotherapy dose escalation results of the ongoing Phase I/II trial of BT8009, a second-generation BTC™ targeting Nectin-4, will be presented at the 2023 American Society for Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium, being held February 16-18, 2023 in San Francisco, California.

Avanos Medical, Inc. (NYSE: AVNS) today announced two executive leadership appointments that support the company’s long-term strategic priorities: Michael Greiner has been named chief transformation officer (in addition to his current responsibilities as senior vice president and chief financial officer), and Kerr Holbrook has been named senior vice president and chief commercial officer.

Zomedica Corp. announced Larry Heaton, CEO, will present and host one-on-one meetings with investors at the Sidoti January Virtual Investor Conference, taking place on January 18-19, 2023.

Emerald Health Pharmaceuticals Inc. has received a positive safety review following a pre-specified interim analysis by the Safety Review Committee (“SRC”) of its Phase 2a study of EHP-101 for systemic sclerosis (“SSc”).

InMode Ltd. announced today that it expects to release its financial results for the fourth quarter and full year 2022 before the Nasdaq market opens on Tuesday, February 14, 2023.

Landos Biopharma, Inc. today announced that an abstract on its Phase 1b Study to evaluate safety, tolerability, pharmacokinetics and clinical efficacy of the Nucleotide-binding oligomerization domain.

COEUS Holdings and its subsidiaries today announced it has appointed Dean Hakanson, MD, to the role of Chief Medical Officer.